Zytiga

Type: Product
Name: Zytiga
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Zytiga cancer drug denied to Welsh patients

WELSH Conservatives have reacted angrily to the news that another life-extending cancer drug may not be available to patients in Wales.The National Institute for Health and Care Excellence (NICE) has issued final draft guidance on the prostate cancer ... [Published Penarth Times - Aug 27 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Mad at NICE's cancer drug rejections? Look to drugmakers, agency chief says

Political shilly-shallying about the cost of drugs has to end, the chief of the U.K.'s cost-effectiveness agency says. Government officials and politicians need to be up front with the public about one stark fact: The country's health service just can't ... [Published FiercePharma - Aug 25 2014]
First reported Aug 23 2014 - Updated Aug 24 2014 - 1 reports

Drug giant incites war of the sexes

A PR representative for a billion-dollar drug company has set up a health funding battle between men and women by claiming breast cancer sufferers get "gold standard" treatment but men with prostate cancer are "sent home to die".The Prostate Cancer Foundation ... [Published Waikato Times - Aug 23 2014]
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

Zytiga Cancer Drug Denied to Welsh Patients

Darren MillarWelsh Conservatives have reacted angrily to the news that another life-extending cancer drug may not be available to patients in Wales.The National Institute for Health and Care Excellence (NICE) has issued final draft guidance on the prostate ... [Published Welsh Icons - Aug 16 2014]
Entities: Zytiga, Cancer, Wales
First reported Aug 15 2014 - Updated Aug 16 2014 - 5 reports

Benefits of Zytiga for men with relapsed prostate cancer dont justify price EU decides

Related Biotechnology, Pharmaceutical and Healthcare NewsThe National Institute for Health and Care Excellence (NICE) for England and Wales yesterday issued final draft guidance recommending against Janssen's Zytiga (abiraterone) to treat patients with ... [Published BioPortfolio - Aug 16 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 2 reports

NICE backs Gilead’s Sovaldi in hepatitis C

NHS patients in England received mixed news today as the region's health watchdog backed a new drug for use in hepatitis C but denied expanded use of another medicine in prostate cancer.The National Institute for Health and Care Excellence (NICE), which ... [Published PMLive - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

NICE failure to agree a Zytiga price with Janssen is 'fiasco'

Medical charity Prostate Cancer UK has reacted angrily to the news that NICE has rejected Janssen's Zytiga for broader use in new draft guidance, dubbing it "a kick in the teeth for men with advanced prostate cancer".The UK's cost-effectiveness watch ... [Published BioPortfolio - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 6 reports

NICE attacked again over refusal to endorse cancer drug

The National Institute for Health and Care Excellence has come under attack for the second time in the space of a week following its refusal to endorse another cancer drug for use on the NHS because it is not cost-effective.Abiraterone, also known as ... [Published Pharmacy.Biz - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

NICE rejection of firstline Zytiga angers Institute of Cancer Research

| SCRIPSir Andrew Dillon, NICE chief executive, said: "We know how important it is for patients to have the option to delay chemotherapy and its associated side effects, so we are disappointed not to be able to recommend abiraterone for use in this w ... [Published BioPortfolio - Aug 15 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Forum Post: Zytiga - advanced prostate cancer

Hi, my Dad is 73 and was diagnosed with APC approx 12 months ago. He has been on hormone therapy tablets and injections, and although his PSA level initially was dramatically reduced, his levels have now gone back up to 500. In the last week we have ... [Published Macmillan Cancer Support - Aug 06 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Revision: 7, Authorised

Entities: Abiraterone, Zytiga
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

One Drug To Rule Them All: Medivation's Xtandi To Dominate Prostate Cancer Market

Summary MDVN's current market cap does not reflect its future dominance of the prostate cancer market. PhII Data showing superiority in the frontline setting is due this summer and is highly likely to be positive. Physician sentiment amongst urologists ... [Published Seeking Alpha - Aug 05 2014]

Quotes

...the news, but also said a sustainable solution for access to cancer drugs was needed, and called on NICE and the pharmaceutical industry to show "greater flexibility and a genuine willingness to work together in the interests of all cancer patients"
"[W]hat we're looking at is an offer from a company and it's just as reasonable for people to question ... that offer as it is to question the reasonableness of the decision that NICE takes" Dillon told the FT
But prostate cancer sufferer Phil Hunt, of Rotorua, said: "We should be equal. Females got their drugs for breast cancer. Why don't men stand up for themselves as well?" Ad Feedback - Sunday Star Times
"The ability of Genzyme to spend 15 years developing the next generation and have the willingness, courage to go for a third generation that might treat a smaller brain population depends on a business model that works" Meeker said

More Content

All (98) | News (85) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Cancer Drugs Fund budget increased – but pharma... [Published pharmaphorum - Aug 28 2014]
Buy What You Know: 6 Consistent Dividend Winner... [Published Daily Finance - Aug 28 2014]
Zytiga cancer drug denied to Welsh patients [Published Penarth Times - Aug 27 2014]
Merck Collaboration Could Add $150M To Advaxis'... [Published Seeking Alpha - Aug 26 2014]
Mad at NICE's cancer drug rejections? Look to d... [Published FiercePharma - Aug 25 2014]
Sell These 5 Stocks on the Verge of Bankruptcy [Published Investors Alley - Aug 24 2014]
Drug giant incites war of the sexes [Published Waikato Times - Aug 23 2014]
Price could be key for Sanofi's new Gaucher pil... [Published FiercePharma - Aug 20 2014]
Sell Side Views On Johnson and Johnson [Published Bidness Etc - Aug 20 2014]
Experts condemn "flawed" NICE process over its ... [Published British Medical Journal - Aug 19 2014]
NICE rejection of abiraterone before chemothera... [Published Medical News Today - Aug 18 2014]
Zytiga Cancer Drug Denied to Welsh Patients [Published Welsh Icons - Aug 16 2014]
Benefits of Zytiga for men with relapsed prosta... [Published BioPortfolio - Aug 16 2014]
Benefits of Zytiga for men with relapsed prosta... [Published MedCity News - Aug 15 2014]
NICE Zytiga snub is 'plainly illogical,' critic... [Published FiercePharma - Aug 15 2014]
NICE failure to agree a Zytiga price with Janss... [Published BioPortfolio - Aug 15 2014]
A Few Reasons Why Investors Should Consider Den... [Published Guru Focus - Aug 15 2014]
Earlier use of Johnson & Johnson's prostate can... [Published FirstWord Pharma - Aug 15 2014]
East Coast Biotech Roundup: Amicus, Accelerator... [Published Xconomy - Aug 15 2014]
National Institute for Clinical Excellence (NIC... [Published BioSpace - Aug 15 2014]
What Do Humans and Laboratory Rats Have in Common? [Published The ASCO Post - Aug 15 2014]
Prostate drug decision highlights urgent need f... [Published Cancer Research UK - Aug 15 2014]
NICE backs Gilead’s Sovaldi in hepatitis C [Published PMLive - Aug 15 2014]
NICE attacked again over refusal to endorse can... [Published Pharmacy.Biz - Aug 15 2014]
Anger over prostate drug ruling [Published OnMedicanet - Aug 15 2014]
NICE rejects Zytiga as prostate cancer treatmen... [Published Hospital Pharmacy Europe - Aug 15 2014]
NICE says benefit of prostate cancer drug Zytig... [Published Pharma Letter - Aug 15 2014]
Charities ‘disappointed’ in NICE and Janssen [Published Pharmafocus - Aug 15 2014]
NICE rejection of firstline Zytiga angers Insti... [Published BioPortfolio - Aug 15 2014]
NICE says benefit of prostate cancer drug Zytig... [Published BioPortfolio - Aug 15 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 06 2014]
Big Pharma Needs Growth: Two Severely Undervalu... [Published Wall St. Cheat Sheet - Jul 05 2014]
Source: Thinkstock At any given moment, there are literally hundreds of severely undervalued companies that are ripe for takeovers. In this article, I will focus on the pharmaceutical industry, where many investors have borth struck it rich when ...
Inside the Lobbyist War on Drug Prices: What In... [Published Wall St. Cheat Sheet - Jun 10 2014]
Source: Getty Images The pharmaceutical and biotech industries are notoriously tricky for investors. The industry is riskier than many others (such as basic materials or consumer goods), and companies’ successes are largely based on drug approvals, ...
Which of These 10 Best Selling Cancer Drugs Are... [Published Wall St. Cheat Sheet - Jun 06 2014]
Source: Thinkstock If you look at the pharmaceutical industry’s most promising investigational drugs (which you can do right here ), cancer therapies comprise the vast majority of the industry’s recent innovations; a fact which is increasingly important ...
IMAAGEN Data Demonstrate that Abiraterone Aceta... [Published PR Newswire: Health - Jun 02 2014]
HORSHAM, Pa., June 2, 2014 /PRNewswire/ -- Abiraterone acetate (ZYTIGA®) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary endpoint of the IMAAGEN trial, which evaluates the investigational use ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.